CA
NZ
UK
AU
IND
US
Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., filed a Form 4 on September 15, 2026, reporting the sale of 1,283 shares of common stock under a Rule 10b5-1 trading plan.
Stephen Michael Kelsey, Senior Advisor to the Chief Executive Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), filed a Form 4 on September 15, 2026, disclosing option exercises and open-market sales of common stock executed on September 11, 2026, pursuant to a Rule 10b5-1 trading plan.
An amended statement of changes in beneficial ownership for Carlsmed, Inc. (NASDAQ:CARL) was filed on September 15, 2026, correcting a prior filing dated July 24, 2025, to report a common stock purchase by Casey M. Tansey that had been omitted due to an administrative …
Robert A. Frist, Jr., CEO and Chairman of HealthStream, Inc. (NASDAQ:HSTM), filed a Form 4 on September 15, 2026, disclosing the sale of 144,068 shares of common stock on September 14, 2026, in a privately negotiated transaction.
Fumihide Esaka, Chief Executive Officer and Director of Ambiq Micro, Inc. (NASDAQ:AMBQ), filed a Form 4 with the SEC disclosing option exercises and open-market sales of common stock on September 11 and September 15, 2026, with the filing signed on September 15, 2026.
A Form 4 filed on September 15, 2026 discloses that Daniel J. Castillo, Executive Vice President and General Manager, EES of WESCO International Inc, had 1,618.0105 shares of common stock withheld on September 11, 2026 to satisfy tax obligations upon the vesting of restricted …
A Form 4 filed on September 15, 2026, discloses that Sean Chihhsiang Chen, President and COO of Ambiq Micro, Inc. (NASDAQ:AMBQ), exercised stock options and sold common stock on September 14, 2026, under a pre-established Rule 10b5-1 trading plan.
A Form 4 filed on September 15, 2026, with the SEC discloses that Zhang Ker, a director of Ambiq Micro, Inc. (AMBQ), sold a total of 10,000 shares of common stock on September 11, 2026.
A statement of changes in beneficial ownership was filed on September 15, 2026, disclosing a transaction by Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc., involving common stock on September 11, 2026.
Douglas Carr, Senior Vice President of Finance and Operations at Century Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 15, 2026, reporting the sale of common stock on September 14, 2026, in connection with the vesting of restricted stock units.
Please wait processing your request...